|
Arthritis, Psoriatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that natively thrombocytopenic <i>Mpl</i><sup>-/-</sup> mice deficient in the thrombopoietin receptor sustain severe lung injury marked by alveolar barrier disruption and hemorrhagic pneumonia with early mortality following acute intrapulmonary <i>Pseudomonas aeruginosa</i> (PA) infection; barrier disruption was attenuated by platelet reconstitution.
|
30733303 |
2019 |
|
Dengue Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
|
31192066 |
2019 |
|
Liver diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
|
29958825 |
2019 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eltrombopag, a thrombopoietin receptor agonist, is effective in chronic immune thrombocytopenia (ITP).The data in lupus ITP are sparse.
|
31166214 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eltrombopag, a thrombopoietin receptor agonist, is effective in chronic immune thrombocytopenia (ITP).The data in lupus ITP are sparse.
|
31166214 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer.
|
30770989 |
2019 |
|
Hemorrhagic pneumonia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that natively thrombocytopenic <i>Mpl</i><sup>-/-</sup> mice deficient in the thrombopoietin receptor sustain severe lung injury marked by alveolar barrier disruption and hemorrhagic pneumonia with early mortality following acute intrapulmonary <i>Pseudomonas aeruginosa</i> (PA) infection; barrier disruption was attenuated by platelet reconstitution.
|
30733303 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer.
|
30770989 |
2019 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eltrombopag, a thrombopoietin receptor agonist, is effective in chronic immune thrombocytopenia (ITP).The data in lupus ITP are sparse.
|
31166214 |
2019 |
|
Deformity of bone
|
0.010 |
Biomarker
|
group |
BEFREE |
Severe grades of MPL may present with bone deformities or abnormal alignments; therefore, evaluation of the measurement methods of femoral and tibial alignment in dogs with different grades of patellar luxation to assess the accuracy and reliability of the measurements could be useful.
|
30921407 |
2019 |
|
Chronic lung disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Treatment of thrombocytopenia with thrombopoietin receptor agonists (TPORAs) seems to be associated with portal vein thrombosis (PVT) in patients with chronic liver disease (CLD).
|
29958825 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003).
|
30770989 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Knockdown of CD110 expression significantly attenuated cell migration and invasion.
|
30770989 |
2019 |
|
Liver regeneration disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The goal of these studies was to support the clinical implementation of platelet agents, such as thrombopoietin receptor agonists, to augment liver regeneration after liver surgery.
|
31720801 |
2019 |
|
Lymphoproliferative Disorder of the Skin
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Treatment of thrombocytopenia with thrombopoietin receptor agonists (TPORAs) seems to be associated with portal vein thrombosis (PVT) in patients with chronic liver disease (CLD).
|
29958825 |
2019 |
|
Antiphospholipid Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.
|
29757439 |
2018 |
|
Chronic idiopathic thrombocytopenic purpura
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eltrombopag is an oral thrombopoietin receptor agonist approved for the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP), who are more than 1 year old, and show poor response to first-line therapy.
|
29683873 |
2018 |
|
Infection caused by Helicobacter pylori
|
0.010 |
Biomarker
|
disease |
BEFREE |
The number of total MAIT and CD4-CD8+ MAIT cells was not correlated with the response to thrombopoietin receptor agonist treatment or with Helicobacter pylori infection.
|
30408105 |
2018 |
|
Bone Marrow failure syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (EP), a small-molecule thrombopoietin receptor (TPO-R) agonist and potent intracellular iron chelator, has shown remarkable efficacy in stimulating sustained multilineage hematopoiesis in patients with bone marrow failure syndromes, suggesting an effect at the most immature hematopoietic stem and multipotent progenitor level.
|
30209246 |
2018 |
|
Immunosuppression
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Eltrombopag, a thrombopoietin receptor agonist, showed activity as a single agent in those refractory to initial immunosuppression with hematologic response rates of 40% to 50%.
|
30047414 |
2018 |
|
TAFRO syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient.
|
29626596 |
2018 |
|
IgE-mediated food allergy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Upstream therapies that shift towards a Th1/Treg response include toll-like receptor (TLR) 4 agonists (e.g., MPL and GLA), TLR9 agonists (CpG oligonucleotides), nanoparticles encapsulating peanut allergen (with and without adjuvants, such as CpG or rapamycin), Chinese herbal medicine (food allergy herbal formula (FAHF-2)), probiotics, and interferon-gamma.
|
29968170 |
2018 |
|
Supraventricular tachycardia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CALR, JAK2<sup>V617F</sup> and thrombopoietin receptor gene (MPL) mutations were analysed in a test cohort that included 312 patients with SVT.
|
28483676 |
2017 |
|
Myelofibrosis due to another disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF.
|
28561069 |
2017 |
|
Thrombocytopenia, cyclic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that the primary change in cyclic thrombocytopenia is an interference with, or destruction of, the thrombopoietin receptor with secondary changes in other processes, including immune-mediated destruction of platelets and megakaryocyte deficiency and failure in platelet production.
|
28391511 |
2017 |